Sotorasib’s Accelerated Approval

This Viewpoint reviews the accelerated approval process and lack of postapproval studies to verify its benefit as it applied to sotorasib, a treatment for non–small cell lung cancer with the KRAS g12c mutation, and recommends measures to ensure confirmatory follow-up studies.